

## MARKERS FOR DETECTION OF GASTRIC CANCER

**Publication number:** WO2005010213

**Publication date:** 2005-02-03

**Inventor:** GUILFORD PARRY JOHN (NZ); HOLYOAKE ANDREW JOHN (NZ)

**Applicant:** PACIFIC EDGE BIOTECHNOLOGY LTD (NZ); FARMER CHARLES DAVIS JR (US); GUILFORD PARRY JOHN (NZ); HOLYOAKE ANDREW JOHN (NZ)

**Classification:**

- **international:** C12Q1/68; C12Q1/68; (IPC1-7): C12Q1/68

- **European:** C12Q1/68M6B

**Application number:** WO2004US22959 20040716

**Priority number(s):** US20030487906P 20030717

**Also published as:**

WO2005010213 (A3)  
 EP1649064 (A3)  
 EP1649064 (A2)  
 EP1649064 (A0)  
 CN1867679 (A)

[more >>](#)


**Cited documents:**

WO9841864  
 XP002317462  
 XP002317463  
 XP002317464  
 XP008042860  
[more >>](#)

[Report a data error here](#)

### Abstract of WO2005010213

Early detection of tumors is a major determinant of survival of patients suffering from tumors, including gastric tumors. Members of the GTM gene family can be over-expressed in gastric tumor tissue and other tumor tissue, and thus can be used as markers for gastric and other types of cancer. GTM proteins can be released from cancer cells, and can reach sufficiently high concentrations in the serum and/or other fluids to permit their detection. Thus, methods and test kits for detection and quantification of GTM can provide a valuable tool for diagnosis of gastric cancer.



Data supplied from the **esp@cenet** database - Worldwide